OTC Revenue Growth of 17%, Beauty.com Growth of 19% and Vision Growth
of 11%
New Customer Growth of 27% Year-Over-Year
BELLEVUE, Wash., Oct. 20, 2009 (GLOBE NEWSWIRE) -- drugstore.com, inc. (Nasdaq:DSCM), a leading online retailer of health, beauty, vision, and pharmacy products, today announced its financial results for the third quarter ended September 27, 2009. The company reported quarterly net sales of $96.8 million, driven by strong OTC and vision sales. Gross margins increased 70 basis points year-over-year to a record 29.3% and the company's net loss in its seasonally softest quarter was $1.6 million, an improvement of $2.0 million from the same period a year ago. The company reported adjusted EBITDA of $3.0 million which compared to $3.6 million reported in the same period of the prior year. 2008 third quarter adjusted EBITDA results included a $3.4 million contribution from the company's discontinued local-pick-up (LPU) business. Adjusted EBITDA is a non-GAAP financial measure defined as earnings before interest, taxes, depreciation, and amortization of intangible assets and non-cash marketing expense, adjusted to exclude the impact of stock-based compensation expense.
"In the third quarter, drugstore.com reported double digit top-line growth as OTC revenues increased by approximately 17% and beauty.com expanded by 19%," said Dawn Lepore, chief executive officer and chairman of the board of drugstore.com, inc. "Our growth was a result of continued strong sales of replenishment and beauty items to our loyal customer base and impressive new customer growth of 27%. This new customer growth was achieved while reducing our marketing cost per new customer to its lowest level since 2007. The initial success of key partnerships contributed to this effort, accounting for roughly 9% of overall new customer additions."
"Gross margins were a record 29.3%, reflecting the continued success of our profitability initiatives, and we reduced operating expenses as a percentage of net sales from the prior year by 310 basis points. As a result, we reported adjusted EBITDA of over $3.0 million, a year-over-year increase of $2.8 million, excluding the EBITDA generated from our discontinued LPU segment in the prior year. Throughout 2009, we have been executing on plan in our core business and continuing to roll out new growth initiatives and partnerships that we believe can add incremental revenue growth, especially in 2010. Most recently, we launched our first microsite -- SexualWellBeing.com(TM) -- and expect to add 5 to 8 more microsites by the end of 2010," concluded Ms. Lepore.
Net loss for the third quarter of 2009 was $1.6 million, or $0.02 per share, compared to a net loss of $3.6 million, or $0.04 per share, for the third quarter of 2008. The third quarter of 2009 net loss includes $1.4 million in non-cash stock-based compensation expense.
Outlook for Fourth Quarter of 2009
For the fourth quarter of 2009, the company is targeting net sales in the range of $107.0 million to $110.0 million, a net loss in the range of $1.8 million to $2.8 million, and adjusted EBITDA in the range of $2.5 million to $3.5 million. Fiscal year 2009 is a 53-week year, with the fourth quarter of 2009 representing a 14-week period.
Financial and Operational Highlights for the Third Quarter of 2009
(All comparisons are made to the third quarter of 2008 and reflect the reporting of the local pick-up business as discontinued operations)
Key Financial Highlights:
-- Gross margins increased 70 basis points to a record 29.3%.
-- Total contribution margin dollars increased by approximately 15%
to $20.4 million.
-- Total orders grew by approximately 15% to 1.5 million, while
contribution margin dollars per order were flat at $14.
-- Operating expenses as a percentage of sales decreased to 31% from
34.1% in the same period last year.
-- Free cash flow increased $14.6 million to positive $7.2 million
for the trailing twelve months compared with negative $7.5 million
for the trailing twelve months ended September 28, 2008.
-- Cash, cash equivalents, and marketable securities were $37.4
million at quarter end.
Net Sales Summary:
-- Total sales increased over 10% to $96.8 million.
-- OTC net sales grew approximately 17% to $71.3 million for the
quarter, including Beauty.com growth of 19%.
-- Vision net sales grew 11% to $17.2 million for the quarter.
-- Mail-order pharmacy net sales were $8.2 million.
-- Average net sales per order were $67. Average net sales per order
remained flat sequentially at $57 for OTC and increased to $118
for vision, and were $163 for mail-order pharmacy.
-- Net sales from repeat customers (1) represented 77% of net sales.
Key Customer Milestones:
-- We served approximately 412,000 new customers, inclusive of our
strategic partnerships, during the quarter, up 27% over the same
period in the prior year.
-- Marketing and sales expense per new customer decreased on both a
sequential and year-over-year basis to approximately $21.50.
-- We have now served approximately 11.1 million customers since
inception.
-- The number of active customers (2) was 2.9 million, up 14% year
over year.
1. Net sales from repeat customers exclude Weil Lifestyle, LLC (Weil)
related Custom Nutrition Services (CNS) net sales and reflect only
the activity of customers making purchases through the Web sites of
drugstore.com, inc. and its subsidiaries.
2. Active customer base reflects those customers who have purchased
at least once within the last 12 months. Both the active customer
base (a trailing 12-month number) and average annual spend per active
customer exclude net sales and orders generated by the company's CNS
fulfillment relationship with Weil, and reflect only the activity of
customers making purchases through the Web sites of drugstore.com,
inc. and its subsidiaries.
Conference Call
Investors, analysts, and other interested parties are invited to join the drugstore.com, inc. quarterly conference call on, October 20, 2009 at 4:30 p.m. ET (1:30 p.m. PT). To participate, callers should dial 877-941-8416 (international callers should dial 480-629-9808) five minutes beforehand. Investors may also listen to the conference call live at http://investor.drugstore.com/, by clicking on the "audio" hyperlink. A replay of the call will be available through Saturday, October 24, 2009 by dialing 800-406-7325 and enter passcode 4166337# and international parties should call 303-590-3030 and enter passcode 4166337# beginning two hours after completion of the call.
Non-GAAP Measures
To supplement the consolidated financial statements presented in accordance with GAAP, drugstore.com, inc. uses the non-GAAP measure of adjusted EBITDA, defined as earnings before interest, taxes, depreciation, and amortization of intangible assets and non-cash marketing expenses, adjusted to exclude the impact of stock-based compensation expense. This non-GAAP measure is provided to enhance the user's overall understanding of the company's current financial performance. Management believes that adjusted EBITDA, as defined, provides useful information to the company and to investors by excluding certain items that may not be indicative of the company's core operating results. In addition, because drugstore.com, inc. has historically provided adjusted EBITDA measures to investors, management believes that including adjusted EBITDA measures provides consistency in the company's financial reporting. However, adjusted EBITDA should not be considered in isolation, or as a substitute for, or as superior to, net income/loss, cash flows, or other consolidated income/loss or cash flow data prepared in accordance with GAAP, or as a measure of the company's profitability or liquidity. Although adjusted EBITDA is frequently used as a measure of operating performance, it is not necessarily comparable to other similarly titled captions of other companies due to differences in methods of calculation. Net income/loss is the closest financial measure prepared by the company in accordance with GAAP in terms of comparability to adjusted EBITDA. A reconciliation of adjusted EBITDA to net income/loss is included with the financial statements attached to this release.
In addition, the company uses the non-GAAP measure of free cash flow, defined as net cash provided by (used in) operating activities plus proceeds from the sale of discontinued operations less purchases of fixed assets as disclosed on our consolidated statements of cash flows. Management believes that free cash flow is an important liquidity metric because it measures, during a given period, the amount of cash generated that is available to service debt obligations, make investments, fund acquisitions and for certain other activities. Free cash flow is not a measure determined in accordance with GAAP and may not be defined or calculated by other companies in the same manner. Additionally, this financial measure is subject to variability quarter over quarter as a result of the timing of payments related to accounts payable, including inventory purchases, and accounts receivable. Since free cash flow includes investments in operating assets, management believes this non-GAAP liquidity metric is useful in addition to the most directly comparable GAAP measure of net cash provided by (used in) operating activities, and should not be used as a substitute for it or any other measure determined in accordance with GAAP. A reconciliation of free cash flow to net cash provided by operating activities is included with the supplemental financial schedules attached to this release.
About drugstore.com, inc.
drugstore.com, inc. (Nasdaq:DSCM) is a leading online retailer of health, beauty, vision, and pharmacy products. Our portfolio of brands includes: drugstore.com(TM), Beauty.com(TM), and VisionDirect.com(TM). All are accessible from http://www.drugstore.com and provide a convenient, private, and informative shopping experience while offering a wide assortment of more than 45,000 products at competitive prices.
The drugstore.com pharmacy is certified by the National Association of Boards of Pharmacy (NABP) as a Verified Internet Pharmacy Practice Site (VIPPS) and operates in compliance with federal and state laws and regulations in the United States.
The drugstore.com, inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6419
The financial results contained in this press release are preliminary and unaudited. In addition, this press release contains forward-looking statements regarding future events or the future financial and operational performance of drugstore.com, inc. Words such as "expect," "target," "believe," "may," "will," "continue," "start," "should," and similar expressions, are intended to identify forward-looking statements. Forward-looking statements are based on current expectations, are not guarantees of future performance and involve assumptions, risks, and uncertainties. Actual performance may differ materially from those contained or implied in such forward-looking statements. Risks and uncertainties that could lead to such differences could include, among other things: effects of changes in the economy, changes in consumer spending, fluctuations in the stock market, changes affecting the Internet, online retailing and advertising, difficulties establishing our brand, and building a critical mass of customers, the unpredictability of future revenues and expenses and potential fluctuations in revenues and operating results, risks related to business combinations and strategic alliances, possible tax liabilities relating to the collection of sales tax, consumer trends, the level of competition, seasonality, the timing and success of expansion efforts, changes in senior management, risks related to systems interruptions, possible governmental regulation, and the ability to manage a growing business. Additional information regarding factors that potentially could affect the business, financial condition, and operating results of drugstore.com, inc. is included in the company's periodic filings with the SEC on Forms 10-K, 10-Q, and 8-K. drugstore.com, inc. expressly disclaims any intent or obligation to update any forward-looking statement, except as otherwise specifically stated by it.
drugstore.com, inc.
Consolidated Statements of Operations
(in thousands, except share and per share data)
(unaudited)
Three Months Ended Nine Months Ended
------------------------- -------------------------
Sept. 27, Sept. 28, Sept. 27, Sept. 28,
2009 2008 2009 2008
------------ ------------ ------------ ------------
Net sales $ 96,815 $ 87,823 $ 295,471 $ 272,639
Costs and
expenses: (1) (2)
Cost of sales 68,408 62,708 210,722 196,570
Fulfillment and
order
processing 11,074 10,968 32,976 32,914
Marketing and
sales 8,854 7,929 27,424 24,491
Technology and
content 6,242 6,009 18,237 16,948
General and
administrative 3,824 4,862 11,401 15,156
Amortization of
intangible
assets 28 206 449 661
------------ ------------ ------------ ------------
Total costs
and expenses 98,430 92,682 301,209 286,740
------------ ------------ ------------ ------------
Operating loss (1,615) (4,859) (5,738) (14,101)
Interest income
(expense), net (19) 137 38 516
------------ ------------ ------------ ------------
Loss from
continuing
operations (1,634) (4,722) (5,700) (13,585)
Income from
discontinued
operations -- 1,103 5,946 5,009
------------ ------------ ------------ ------------
Net income (loss) $ (1,634) $ (3,619) $ 246 $ (8,576)
============ ============ ============ ============
Basic and diluted
net loss per
share $ (0.02) $ (0.04) $ 0.00 $ (0.09)
============ ============ ============ ============
Weighted average
shares used in
computation of:
Basic and
dilutive net
loss per share 96,932,740 96,515,737 99,000,725 96,462,259
============ ============ ============ ============
---------
(1) Set forth below are the amounts of stock-based compensation by
operating function recorded in the Statements of Operations:
Fulfillment and
order
processing $ 134 $ 152 $ 348 $ 440
Marketing and
sales 383 416 1,039 1,148
Technology and
content 292 326 756 930
General and
administrative 603 952 1,358 3,260
------------ ------------ ------------ ------------
$ 1,412 $ 1,846 $ 3,501 $ 5,778
============ ============ ============ ============
(2) Set forth below are the amounts of depreciation by operating
function recorded in the Statements of Operations:
Fulfillment and
order
processing $ 750 $ 769 $ 2,241 $ 1,913
Marketing and
sales 1 1 3 3
Technology and
content 2,350 2,137 6,910 5,618
General and
administrative 110 136 333 361
------------ ------------ ------------ ------------
$ 3,211 $ 3,043 $ 9,487 $ 7,895
============ ============ ============ ============
SUPPLEMENTAL INFORMATION: Gross Profit and Gross Margin Information:
Three Months Ended Nine Months Ended
(In thousands, ------------------------- -------------------------
unless otherwise Sept. 27, Sept. 28, Sept. 27, Sept. 28,
indicated) 2009 2008 2009 2008
------------ ------------ ------------ ------------
Net sales $ 96,815 $ 87,823 $ 295,471 $ 272,639
Cost of sales 68,408 62,708 210,722 196,570
------------ ------------ ------------ ------------
Gross profit $ 28,407 $ 25,115 $ 84,749 $ 76,069
============ ============ ============ ============
Gross margin 29.3% 28.6% 28.7% 27.9%
============ ============ ============ ============
SUPPLEMENTAL INFORMATION: Segment Information:
Three Months Ended Nine Months Ended
------------------------- -------------------------
Sept. 27, Sept. 28, Sept. 27, Sept. 28,
2009 2008 2009 2008
------------ ------------ ------------ ------------
Net sales:
Over-the-Counter
(OTC) $ 71,349 $ 61,223 $ 214,735 $ 190,985
Vision 17,227 15,579 52,249 46,865
Mail-order
pharmacy 8,239 11,021 28,487 34,789
------------ ------------ ------------ ------------
$ 96,815 $ 87,823 $ 295,471 $ 272,639
Cost of sales:
Over-the-Counter
(OTC) $ 48,702 $ 41,858 $ 147,316 $ 131,970
Vision 13,235 11,888 40,187 36,154
Mail-order
pharmacy 6,471 8,962 23,219 28,446
------------ ------------ ------------ ------------
$ 68,408 $ 62,708 $ 210,722 $ 196,570
Gross profit:
Over-the-Counter
(OTC) 22,647 19,365 67,419 59,015
Vision 3,992 3,691 12,062 10,711
Mail-order
pharmacy 1,768 2,059 5,268 6,343
------------ ------------ ------------ ------------
$ 28,407 $ 25,115 $ 84,749 $ 76,069
============ ============ ============ ============
Gross margin:
Over-the-Counter
(OTC) 31.7% 31.6% 31.4% 30.9%
Vision 23.2% 23.7% 23.1% 22.9%
Mail-order
pharmacy 21.5% 18.7% 18.5% 18.2%
------------ ------------ ------------ ------------
29.3% 28.6% 28.7% 27.9%
============ ============ ============ ============
Variable order
costs:
Over-the-Counter
(OTC) $ 6,541 $ 5,677 $ 19,361 $ 17,511
Vision 785 745 2,348 2,235
Mail-order
pharmacy 681 904 2,056 2,737
------------ ------------ ------------ ------------
8,007 7,326 23,765 22,483
Contribution
margin:
Over-the-Counter
(OTC) $ 16,106 $ 13,688 $ 48,058 $ 41,504
Vision 3,207 2,946 9,714 8,476
Mail-order
pharmacy 1,087 1,155 3,212 3,606
------------ ------------ ------------ ------------
$ 20,400 $ 17,789 $ 60,984 $ 53,586
============ ============ ============ ============
SUPPLEMENTAL INFORMATION: Reconciliation of Net Income (Loss) to
Adjusted EBITDA (See Note 3 below):
Three Months Ended Nine Months Ended
(In thousands, ------------------------- -------------------------
unless otherwise Sept. 27, Sept. 28, Sept. 27, Sept. 28,
indicated) 2009 2008 2009 2008
------------ ------------ ------------ ------------
Net income (loss) $ (1,634) $ (3,619) $ 246 $ (8,576)
Amortization of
intangible assets 28 206 449 661
Amortization of
non-cash
marketing -- 2,290 -- 3,435
Stock-based
compensation 1,412 1,846 3,501 5,778
Depreciation 3,211 3,043 9,487 7,895
Interest income
(expense), net 19 (137) (38) (516)
------------ ------------ ------------ ------------
Adjusted EBITDA $ 3,036 $ 3,629 $ 13,645 $ 8,677
============ ============ ============ ============
NOTE 3: Supplemental information related to the company's adjusted
EBITDA for the three and nine months ended September 27, 2009 and
September 28, 2008 is presented for informational purposes only and
is not prepared in accordance with generally accepted accounting
principles. Adjusted EBITDA is defined as loss before interest,
taxes, depreciation, and amortization of intangible assets and
non-cash marketing expense, adjusted to exclude the impact of
stock-based compensation expense.
SUPPLEMENTAL INFORMATION: Reconciliation of Forecasted Q4 2009 Net Loss
Range to Forecasted Q4 2009 Adjusted EBITDA Range (See Note 4 below):
Range Calculated As: Three Months Ended
January 3, 2010
-------------------
(In thousands, Range Range
unless otherwise indicated) High Low
-------- --------
Net loss $(1,800) $(2,800)
Amortization of intangible assets 30 30
Stock-based compensation 1,750 1,750
Depreciation 3,500 3,500
Interest income (expense), net 20 20
-------- --------
Adjusted EBITDA $ 3,500 $ 2,500
======== ========
NOTE 4: Fiscal year 2009 is a 53-week year with Q4 2009
representing a 14-week quarter.
SUPPLEMENTAL INFORMATION: Reconciliation of Net Cash Provided by
Operating Activities to Free Cash Flow:
Trailing
Three Months Ended Twelve Months Ended
(In thousands, ------------------------- -------------------------
unless otherwise Sept. 27, Sept. 28, Sept. 27, Sept. 28,
indicated) 2009 2008 2009 2008
------------ ------------ ------------ ------------
Net cash provided
by operating
activities $ 783 $ 1,907 $ 5,209 $ 7,053
Add: Proceeds from
sale of
discontinued
operations -- -- 9,910 --
Less: Purchase of
fixed assets (2,119) (2,947) (7,946) (14,529)
------------ ------------ ------------ ------------
Free Cash Flow $ (1,336) $ (1,040) $ 7,173 $ (7,476)
============ ============ ============ ============
drugstore.com, inc.
Consolidated Balance Sheets
(in thousands, except share data)
Sept. 27, Dec. 28,
2009 2008
------------ ------------
(unaudited) (audited)
ASSETS
Current assets:
Cash and cash equivalents $ 21,346 $ 25,197
Marketable securities 16,013 12,997
Accounts receivable, net of allowances 10,922 9,108
Inventories 32,467 32,704
Other current assets 2,783 2,128
Assets of discontinued operations -- 5,954
------------ ------------
Total current assets 83,531 88,088
Fixed assets, net 24,810 28,306
Other intangible assets, net 3,426 3,731
Goodwill 32,202 32,202
Other long-term assets 219 222
------------ ------------
Total assets $ 144,188 $ 152,549
============ ============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 31,054 $ 31,208
Accrued compensation 4,203 4,416
Accrued marketing expenses 4,492 4,630
Other current liabilities 1,427 4,560
Current portion of long-term debt 431 2,998
Liabilities of discontinued operations -- 5,946
------------ ------------
Total current liabilities 41,607 53,758
Long-term debt, less current portion 3,021 2,567
Deferred income taxes 958 953
Other long-term liabilities 1,154 1,071
Stockholders' equity:
Common stock, $.0001 par value, stated at
amounts paid in: Authorized shares -
250,000,000 Issued shares - 99,993,377
and 96,547,079 Outstanding shares -
99,887,958 and 96,547,079 as of September
27, 2009 and December 28, 2008,
respectively 867,260 864,282
Treasury stock - 105,419 shares as of
September 27, 2009 (151) --
Accumulated other comprehensive income
(loss) (53) 57
Accumulated deficit (769,608) (770,139)
------------ ------------
Total stockholders' equity 97,448 94,200
------------ ------------
Total liabilities and stockholders'
equity $ 144,188 $ 152,549
============ ============
drugstore.com, inc.
Consolidated Statements of Cash Flows
(in thousands)
Three Months Ended Nine Months Ended
------------------------- -------------------------
Sept. 27, Sept. 28, Sept. 27, Sept. 28,
2009 2008 2009 2008
------------ ------------ ------------ ------------
(unaudited)
Operating
activities:
Net income
(loss) $ (1,634) $ (3,619) $ 246 $ (8,576)
Adjustments to
reconcile net
income (loss)
to net cash
provided by
operating
activities:
Depreciation 3,211 3,043 9,487 7,895
Amortization
of intangible
assets 28 206 449 661
Stock-based
compensation 1,412 1,846 3,501 5,778
Other, net 37 (28) (15) (43)
Changes in:
Accounts
receivable (142) 96 (1,814) (11)
Inventories (2,167) 107 237 498
Other assets 284 (337) (655) 459
Accounts
payable,
accrued
expenses
and other
liabilities (246) (970) (3,887) (2,914)
Net cash
provided by
activities
of
discontinued
operations -- 1,563 (5,946) 2,560
------------ ------------ ------------ ------------
Net cash
provided by
operating
activities 783 1,907 1,603 6,307
Investing
activities:
Purchases of
marketable
securities (1,985) (7,772) (13,138) (43,116)
Sales and
maturities of
marketable
securities 1,400 15,606 10,049 49,704
Proceeds from
sale of
discontinued
operations -- -- 5,946 --
Purchases of
fixed assets (2,119) (2,947) (5,812) (11,063)
Purchases of
intangible
assets -- -- (145) --
------------ ------------ ------------ ------------
Net cash (used
in) provided
by investing
activities (2,704) 4,887 (3,100) (4,475)
------------ ------------ ------------ ------------
Financing
activities:
Proceeds from
exercise of
stock options
and employee
stock purchase
plan 3 102 97 525
Proceeds from
line of credit 2,986 1,500 2,986 5,000
Principal
payments on
capital leases,
term loan
obligations and
line of credit (3,755) (2,339) (5,286) (3,557)
Purchase of
treasury stock -- -- (151) --
------------ ------------ ------------ ------------
Net cash (used
in) provided
by financing
activities (766) (737) (2,354) 1,968
------------ ------------ ------------ ------------
Net increase
(decrease)
in cash
and cash
equiva-
lents (2,687) 6,057 (3,851) 3,800
Cash and
cash
equiva-
lents,
beginning
of period 24,033 16,315 25,197 18,572
------------ ------------ ------------ ------------
Cash and
cash
equiva-
lents, end
of period $ 21,346 $ 22,372 $ 21,346 $ 22,372
============ ============ ============ ============